Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

Users are experiencing increased hair shedding despite using treatments like dutasteride, finasteride, minoxidil, hair vitamins, and DHT shampoo. Some note this happens seasonally, while others are concerned their treatments are no longer effective.

A user is experiencing hair regrowth after 2.5 months using dutasteride and a daily spray containing finasteride, minoxidil, biotin, and ketoconazole. They are optimistic about continued progress and have noticed new dark hairs forming.

The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

A young man faces severe hair loss in his early 20s, using treatments like dutasteride and minoxidil with little success, impacting his self-esteem and relationships. He considers hair systems and therapy as potential solutions.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.

Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.

The conversation is about using dutasteride mesotherapy with a dermaroller for treating a receding hairline, especially on the temples. The user is seeking advice on its effectiveness.

Exosomes are being discussed as a potential hair loss treatment, with some users skeptical about their effectiveness and stability. There is interest in different types of exosomes, including those derived from centella asiatica, and comparisons are made to other treatments like finasteride.

User seeks reputable international finasteride seller due to dermatologists refusing prescription. Dermatologists suggested PRP or exosomes instead.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

The user shared their 5-year hair recovery journey using finasteride, RU58841, dutasteride, minoxidil, and microneedling, noting mixed progress but overall improvement. They regret not starting treatment earlier and recently received positive health feedback from their doctor.

A user underwent a 2,550 FUE hair transplant and started taking dutasteride 0.5mg. They previously tried RU58841, minoxidil, and microneedling but avoided finasteride and dutasteride due to side effects.

The conversation discusses the impact of hair loss treatments like dutasteride and finasteride, with some users expressing skepticism about media claims linking these drugs to severe side effects like suicidal ideation. Many participants criticize the media, particularly British tabloids, for fearmongering and emphasize the psychological impact of hair loss itself.

The conversation is about finding affordable topical anti-androgens for hair loss. The user is currently using finasteride, dutasteride, and oral minoxidil, and is advised that additional topical treatments may not be necessary.

A user shared an extensive hair loss treatment regimen including dutasteride, minoxidil, tadalafil, RU58841, microneedling, and various topical and oral supplements. Responses varied, with some suggesting the regimen is excessive and others offering additional advice or expressing skepticism about its practicality and effectiveness.

An 18-year-old is using 0.5 mg dutasteride daily and 5 mg oral minoxidil for hair loss, noticing progress without side effects after three months. They plan to continue treatment for a year before considering other options like a transplant.

Long-term users of dutasteride, often combined with minoxidil, report mixed results in managing hair loss, with some experiencing side effects like stomach pain and dark circles. Despite increasing dosages, many still face receding hairlines, suggesting genetic factors may play a significant role.

Missing one day of finasteride is humorously discussed, with suggestions to use additional treatments like dutasteride, RU58841, minoxidil, and microneedling. Some users jokingly suggest shaving the head or traveling for hair restoration.

A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

Dutasteride may not be effective for everyone due to underlying issues, suggesting scalp biopsies for further diagnosis. Users discuss using higher doses of dutasteride, topical treatments, minoxidil, and pyrilutamide for hair loss management.

A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.

The user is using Avodart Dutasteride 0.5mg and Roma Minoxidil 2.5mg to combat hair loss, with advice suggesting this combination is effective but may take 3-6 months to show results. The user is considering whether to continue the treatment or buzz their hair, seeking reassurance and advice from others.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user has been taking 0.5 mg of finasteride daily for two months and is experiencing testicular ache, which they believe might be related to the medication. They plan to continue the treatment for a few more months despite the discomfort, hoping the side effects will subside.